Cerebrolysin
Neurotrophic peptide preparation (porcine-brain-derived)
A neuropeptide preparation studied in neurological research.
Also referenced as: FPF-1070
Overview
Cerebrolysin is a peptide preparation produced by enzymatic breakdown of purified porcine brain proteins, manufactured by EVER Pharma. It has been used clinically in a number of countries, particularly in Europe and Asia.
At a glance
What Cerebrolysin does
Cerebrolysin is not a single peptide but a standardized mixture produced by enzymatic hydrolysis of purified porcine brain proteins. Roughly a quarter of it is low-molecular-weight bioactive peptide fragments (under ~10,000 Da) and the remainder is free amino acids. What it does in research is act as a neurotrophic-like agent: it supports neuronal survival, synaptic plasticity, and functional recovery after brain injury, and is used clinically (in several countries) for stroke, dementia, and traumatic brain injury.
Mechanistically, Cerebrolysin appears to mimic and amplify the action of endogenous neurotrophic factors. Its peptide fraction is reported to interact with Trk receptor signaling (TrkA, TrkB), activating the downstream MAPK/ERK and PI3K/Akt cascades that govern neuronal survival, differentiation, and synaptogenesis. It has been shown to upregulate BDNF, GDNF, NGF, IGF-1, and VEGF while downregulating pro-inflammatory signaling such as TNF-alpha, and to reduce excitotoxicity, oxidative stress, and apoptosis. It also appears to modulate amyloid processing and support neurogenesis in some models, which is why it is studied in Alzheimer's and vascular dementia.
The clinical evidence is more substantial than most peptides here but genuinely mixed. Meta-analyses of stroke trials report significant improvement in neurological outcome, and it lowered mortality/severe disability in badly-affected patients, yet the large CASTA trial failed to beat placebo on its primary endpoint. Because it is a complex biological mixture rather than a defined molecule, batch standardization and mechanism attribution remain caveats.
Effects reported in research
- Improved neurological outcome after ischemic stroke in randomized-trial meta-analyses (human).
- Reduced mortality and severe disability in the most severely affected stroke patients, though it missed the CASTA primary endpoint (human).
- Upregulation of BDNF, GDNF, NGF, IGF-1, and VEGF neurotrophic/angiogenic factors (preclinical and clinical biomarker data).
- Activation of TrkA/TrkB receptor signaling and downstream MAPK/ERK and PI3K/Akt survival cascades (preclinical).
- Downregulation of pro-inflammatory TNF-alpha and reduction of excitotoxic and oxidative damage (preclinical).
- Reduced apoptosis and support of neurogenesis in brain-injury and dementia models (animal).
- Studied cognitive and functional benefit in Alzheimer's and vascular dementia trials, with modest and variable effect sizes (human).
- Supportive data in traumatic brain injury recovery (human, mixed-quality trials).
Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.
Mechanism of action
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids rather than a single defined peptide. It is reported to exert neurotrophic and neuroprotective effects with a proposed mechanism resembling that of endogenous neurotrophic factors, potentially influencing neuronal survival, plasticity, and repair. The precise active components and mechanisms are not fully defined.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which Cerebrolysin appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- A complex mixture of peptides and amino acids, not a single defined molecule
- Derived from enzymatically processed porcine brain tissue
- Used clinically in several countries in Europe, Asia, and elsewhere
- Studied in randomized trials for stroke, dementia, and TBI with mixed/debated results
- Not FDA-approved in the United States
Reported research dosing reference only
Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. Cerebrolysin is a research compound.
Cerebrolysin is dosed by volume of the standardized solution rather than by peptide mass, with research protocols spanning single-digit to several-tens-of-milliliters per day given IV/IM. These are reference figures for research context only, not human dosing guidance.
- General research reference: ~5-30 mL/day IV or IM
- Acute stroke research protocols: ~20-50 mL/day IV infusion for ~10-21 days
As a mixture it has no single half-life; the peptide fraction is often cited around 2-4 hours
How it compares
Cerebrolysin is a biologically derived multi-component preparation rather than a single synthetic peptide, distinguishing it from defined molecules like Semax or Dihexa.
Commonly studied alongside
Compounds frequently researched together with Cerebrolysin in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Compare and calculate
Side-by-side pages for the pairings the literature already documents for Cerebrolysin, plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
Cerebrolysin sits in the Cognitive & Nootropic area of the PeptiDex library.
- Entry type: Research compound reference
- Cognitive & Nootropic category hub →
- Browse the full library →
- Glossary of terms →
Where researchers source Cerebrolysin
For researchers studying Cerebrolysin, third-party suppliers such as Practically Natty Peptides offer research-grade material, third-party tests every batch and provides Certificates of Analysis on request, and ship from the US. This specific listing is currently marked out of stock — check the supplier site for current availability.
View research-supplier listing →
Outbound link to a third-party research supplier. Inclusion does not constitute endorsement; all editorial content is developed independently.
Frequently asked questions
What is Cerebrolysin?
Cerebrolysin is not a single peptide but a porcine brain-derived preparation produced by controlled enzymatic proteolysis of lipid-free brain proteins. It is a mixture of roughly 75% free amino acids and 25% low-molecular-weight peptides, studied for neurotrophic-factor-like activity.
What is Cerebrolysin studied for?
Cerebrolysin is studied in models and clinical research of ischemic stroke, traumatic brain injury, and neurodegenerative conditions such as Alzheimer's disease. Reported mechanisms include promotion of neurogenesis, synaptogenesis, and upregulation of neurotrophic signaling such as BDNF.
How is Cerebrolysin administered in research?
Because it is a liquid biologic mixture rather than a lyophilized single peptide, Cerebrolysin is administered parenterally in research, typically by intravenous infusion or intramuscular injection. It is supplied as a ready-to-use solution, so no reconstitution of a powder is involved.
Is Cerebrolysin an approved drug?
Cerebrolysin is approved and marketed in a number of countries outside the United States for stroke, TBI, and dementia indications, but it is not FDA-approved. Regulatory status varies substantially by jurisdiction.
Why can't a single sequence or molecular weight be given for Cerebrolysin?
Because Cerebrolysin is a heterogeneous mixture of many free amino acids and short peptides, it has no single defining sequence or molecular weight. It is characterized instead by its composition profile and its low-molecular-weight peptide fraction.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.
References
Primary literature indexed in PubMed for Cerebrolysin. Listing a study records that it exists and is indexed — it is not a claim of efficacy, a therapeutic indication, or an endorsement of its conclusions. Much of this literature is preclinical (in-vitro or animal-model).
- Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin
- The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders
Each reference was checked against its PubMed record on 2026-07-28: the PMID resolves and the title, journal and year match. Where no indexed literature exists for a compound, PeptiDex says so rather than substituting a citation about a different molecule. See the editorial policy.